Harmony Biosciences (HRMY) Misses Q4 EPS by 29c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.57, $0.29 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $243.8 million versus the consensus estimate of $239.23 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Anthropic Expected to Tell Investors It Sees a More Than $30T Total Addressable Market - WSJ
• TD Cowen Upgrades Bank of Nova Scotia (BNS:CN) (BNS) to Buy
• The Marzetti Company (MZTI) Tops Q2 EPS by 6c